Mer­ck KGaA goes toe to toe with No­var­tis as FDA green-lights MET in­hibitor

5 years ago
Pharma
FDA+

Se­nior Ab­b­Vie li­ai­son quits job to launch neu­ro start­up, with sights set on ALS

5 years ago
Financing

Prothena re­vives its for­mer lead drug, aim­ing for a small­er pop­u­la­tion with more se­vere cas­es

5 years ago
FDA+

Re­call re­port: Apo­tex re­calls 2 batch­es of blood-thin­ner in­jec­tion af­ter sy­ringe mis­la­bel­ing sna­fu

5 years ago
FDA+
Manufacturing

Year-end earn­ings show tur­bu­lent times for Hal Bar­ron's Glax­o­SmithK­line turn­around

5 years ago
Pharma

Mu­ta­bilis re­ceives CARB-X grant for 'night­mare bac­te­ri­a' treat­ment; Ab­Sci and Xyphos shake hands on dis­cov­ery deal

5 years ago
News Briefing

In­novent and Lil­ly win sec­ond Chi­na OK for Tyvyt in front­line NSCLC, ramp­ing up pres­sure on king Keytru­da

5 years ago
China
FDA+

Mads Krogs­gaard Thom­sen hands off CSO job at No­vo Nordisk af­ter a 30-year run, then piv­ots to CEO post at huge No­vo ...

5 years ago
People

Roche and Genen­tech's lat­est AI col­lab­o­ra­tor rais­es $25M Se­ries A to rein­vent one of the old­est can­cer tar­gets

5 years ago
Financing
AI

Bio­gen sweeps out a Parkin­son’s drug on PhII fail­ure as an­a­lysts raise alarms about pro­ject­ed rev­enue slide — ...

5 years ago
R&D

Bris­tol My­ers Squibb turns in pri­or­i­ty re­view vouch­er for sup­ple­men­tal in­di­ca­tion on an old Cel­gene drug

5 years ago
FDA+

Covid-19 roundup: EU re­stric­tions al­ready hav­ing im­pact, Japan says; Mod­er­na seeks to up vial ca­pac­i­ty, sees ...

5 years ago
Coronavirus

Jazz vaults in­to the cannabi­noid field with $7.2B GW Phar­ma buy­out

5 years ago
Deals

EU mis­tak­en­ly leaves key parts of As­traZeneca Covid-19 con­tract unredact­ed, re­veal­ing costs and So­ri­ot's ...

5 years ago
Coronavirus

Biotech scan­dal drags on as the feds on­ly score par­tial vic­to­ry against ex­ecs charged with cook­ing the books

5 years ago
People

Ea­ger to re­deem its Covid-19 vac­cine, As­traZeneca touts 82.4% ef­fi­ca­cy for 12-week dos­ing sched­ule — but will the ...

5 years ago
R&D
Coronavirus

Af­ter rais­ing $465M, Kurt von Em­ster talks about mon­ey, bio­phar­ma and a new breed of in­vestor: 'The ris­ing tide is ...

5 years ago
Deals

Glax­o­SmithK­line dou­bles down on Cure­Vac's mR­NA tech, bets $180M on the hunt for next-gen vac­cine

5 years ago
Deals
Coronavirus

Am­gen scraps or halts a slate of 5 can­cer stud­ies in a se­ries of set­backs. But ex­ecs fo­cus on mas­ter­ing 'in­duced ...

5 years ago
R&D

Neu­ro­crine ax­es Parkin­son's col­lab with Voy­ager af­ter safe­ty is­sues, jeop­ar­diz­ing biotech's long-run­ning cen­ter­piece

5 years ago
Pharma

James Sabry adds an­oth­er weapon to Roche-Genen­tech ar­se­nal; Dai­ichi Sankyo adds ADC #6

5 years ago
News Briefing

Mar­tin Shkre­li’s old com­pa­ny touts PhI­II win, guns for ac­cel­er­at­ed ap­proval

5 years ago
R&D

WuXi STA snaps up Bris­tol My­ers Squibb fa­cil­i­ty, plants feet in Eu­ro­pean CD­MO mar­ket­place

5 years ago
Deals
Manufacturing

FDA lifts clin­i­cal hold on Mus­tang Bio's lentivi­ral gene ther­a­py, paving the way for quick jump in­to piv­otal tri­al

5 years ago
Cell/Gene Tx
FDA+
First page Previous page 739740741742743744745 Next page Last page
A service from the Financial Times